AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind
Executive Summary
Though momentum is building for IDO/PD-1 combos, it's still early days for new immunotherapy programs. Clinicians and investors weigh in on the latest data from the American Association for Cancer Research meeting and the state of the immuno-oncology field.
You may also be interested in...
NewLink Absorbs Big Blow As Roche Exits IDO Inhibitor Partnership
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.
Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now
FDA's approval of Merck's Keytruda/chemo combo based on Phase II data secures the company's position in the prized first-line lung cancer indication, but Phase III readouts from other combination trials are right around the corner.
Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial
NewLink is hoping FDA will accept its plans to run one Phase III registrational study of its IDO pathway inhibitor indoximod with an anti-PD-1 agent in frontline melanoma; Incyte updates its Phase III plans for epacadostat.